The FDA has approved Neurocrine Biosciences’ Crenessity, a new therapy for rare endocrine disorder Congenital Adrenal Hyperplasia (CAH). Designed to block the corticotropin-releasing factor type 1 receptor and thus inhibit secretion of ACTH, the drug reduces the production of adrenal androgens. Crenessity, which comes in a twice-daily pill formula for adults and an oral solution for children aged four and older, is the first new CAH treatment in 70 years.
This Nasty Android Malware Is Picking Up Pace and Targeting Certain Devices
The German Federal Office of Information Security has reported an increase in Android and IoT devices sold with BadBox malware pre-installed. The malware, undetectable through
